249,95€ plus VAT
The Rapid Biocredit Antigen Test from RapiGEN, South Korea, offers a fast and reliable solution for detection of SARS-CoV-2 antigen in remote applications and without the need for complex laboratory instruments at efficient cost and convenience.
|ab VPE 10||10 - 19||10% 224,96€|
|ab VPE 20||20 - 99||15% 212,46€|
|ab VPE 100||100 - 239||20% 199,96€|
|ab VPE 240||240 - 479||25% 187,46€|
|ab VPE 480||480 +||33% 167,47€|
CE Dokument COVID-19 Ag
CE DoC_BIOCREDIT COVID-19 Ag.pdf
PDF-Document [12.3 KB]
EU Produkt Zertifikat COVID-19 Ag
RapiGEN Certificate of EU product notifi[…]
PDF-Document [382.0 KB]
BIOCREDIT COVID-19 Ag Gebrauchsanleitung
PDF-Document [443 KB]
One Step SARS-CoV‑2 Antigen Rapid Test Biocredit – 20 Pack test
BIOCREDIT COVID-19 Ag is a lateral flow immunochromatographic assay that adopted dual color system. The test contains colloid gold conjugate pad and a membrane strip pre-coated with antibodies specific to SARS-CoV‑2 antigen on the test lines (T). If SARS-CoV‑2 antigen is present in the specimen, a visible black band appears on the test lines (T) as antibody-antigen-antibody gold conjugate complex forms. The control line © is used for procedural control and should always appear if the test is performed correctly. For the qualitative detection of SARS-CoV‑2 antigen from nasopharyngeal swab specimen with results in just 5 minutes.
BIOCREDIT COVID-19 Ag has been evaluated with panel specimen by PCR. The results have shown Sensitivity levels of 92.0% and Specificity of 98%.
The Rapid Biocredit Antigen Test from RapiGEN, South Korea, offers a fast and reliable solution for detection of SARS-CoV‑2 antigen in remote applications and without the need for complex laboratory instruments at efficient cost and conveience.
BIOCREDIT COVID-19 Ag has been evaluated with panel specimen by PCR. The results are summarized in the following table:
Sensitivity and Specificity
Interpretation of Results:
BIOCREDIT COVID-19 Ag has been tested with 20 potentially cross reacting microorganisms and viruses. The results showed that BIOCREDIT COVID-19 Ag had no cross-reaction with microorganisms and viruses except very weak cross reacting with SARS-coronavirus.
BIOCREDIT COVID-19 Ag has been tested with 14 potentially interfering endogenous or exogenous substances. The results showed that BIOCREDIT COVID-19 Ag had no interference with endogenous or exogenous substances except very weak interference with HAMA Type I.
Manufacturer: RapiGEN Inc., 2F, 25, Heungan-daero, Gunpo-si, Gyeonggi-do 15809, Republic of Korea
European Representative: MT Promedt Consulting GmbH, Altenhofstrasse. 80, 66386 St. Ingbert, Germany
Distribution Pharmacies: Weko Pharma GmbH, Hochwaldblick 3–4, 54331 Pellingen
This offer is exclusive to commercial customers with qualified personel. This includes: Doctors, outpatient and inpatient facilities in health care, e.g. physiotherapy clinics, wholesalers and pharmacies, health authorities of the federal government, the federal states, the municipalities and municipal associations, blood donation services, pharmaceutical companies, advisory and test facilities for at risk people.
You confirm that you are placing the order for commercial/medical purposes and that you are handing over the products to the appropriate qualified personel.
Please note that due to high demand, delivery may be take longer than expected.
The regular delivery time is 3–5 work days.
129,95€ plus VAT
GENEDIA W COVID-19 Ag device is a chromatographic immunoassay for the qualitative detection of specific antigens to COVID-19 present in human nasopharyngeal swab and sputum. (20 Tests/Kit)